Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TONIC-2: Immune Induction in TNBC
NCT04159818Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in triple-negative breast cancer (TNBC) (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Progression Free Survival at 12 months. Started Feb 2020; status: recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04159818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04159818.